CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript

Core Insights - The company reported a 100% increase in revenue to SGD 156,000 for the six months ended June 30, 2025 [2] - A net loss of $2.05 million was recorded, which could be reduced to $1.44 million when excluding certain costs [2] - Cash and bank balances stood at $2.86 million as of June 30, 2025, with a net tangible asset (NTA) of $7.15 million [2] Financial Performance Overview - Revenue for the first half of 2025 was generated from private banking services after acquiring the necessary license and assets [3] - Other operating income decreased by 8.5% year-on-year [2] - Loss per share was reported at $0.19 for the six months ended June 30, 2025 [2]